Codeine is a naturally occurring phenanthrene alkaloid extracted from the opium poppy (amapola durmiente<\/i>) or synthesized through the $O$<\/span>-methylation of morphine. Under the Anatomical Therapeutic Chemical (ATC) classification system, codeine is indexed under R05DA04 (cough suppressants) and N02AJ06 (analgesics in combination with non-opioids).<\/p>\n Chemically designated as (5$\\alpha$,6$\\alpha$)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol phosphate hemihydrate, codeine phosphate is a water-soluble salt. The 10 mg strength represents a low single-dose unit, widely utilized as an oral antitussive or as part of low-dose combination analgesic regimens. Under the UK Human Medicines Regulations 2012, codeine 10 mg as a single active ingredient is classified as a Prescription Only Medicine (POM). In certain jurisdictions, specific low-dose combination products containing 10 mg per unit with paracetamol or ibuprofen may be classified under Pharmacy (P) regulations subject to strict packet-size controls.<\/p>\n Codeine functions as a prodrug with low intrinsic affinity for opioid receptors. Its therapeutic efficacy is derived primarily from its hepatic conversion into morphine, a full agonist at $\\mu$<\/span>-opioid receptors.<\/p>\n Morphine binding to $\\mu$<\/span>-opioid receptors initiates G-protein-coupled signaling that inhibits adenylyl cyclase, lowers intracellular cAMP, closes presynaptic voltage-gated calcium channels, and opens postsynaptic potassium channels. This hyperpolarises primary afferent nociceptors, inhibiting the release of excitatory neurotransmitters (substance P, glutamate) in the dorsal horn of the spinal cord.<\/p>\n At lower concentrations (such as those achieved with 10 mg doses), codeine acts directly on the medullary cough center to reduce the cough reflex threshold without compromising overall airway clearance mechanisms.<\/p>\n Licensing for oral codeine phosphate 10 mg includes:<\/p>\n Symptomatic Relief of Dry Cough:<\/b> Suppression of distressing, non-productive cough in adults.<\/p>\n<\/li>\n Mild-to-Moderate Pain:<\/b> Treatment of acute, mild-to-moderate pain (often co-formulated with paracetamol or non-steroidal anti-inflammatory drugs) when non-opioid monotherapy is insufficient.<\/p>\n<\/li>\n<\/ul>\n Genotype and Age Safety Restrictions:<\/i> Codeine is strictly contraindicated in children under 12 years of age for any indication due to unpredictable risks of fatal respiratory depression. In adolescents aged 12 to 18 years, codeine is contraindicated if respiratory function is compromised (e.g., severe asthma, post-tonsillectomy\/adenoidectomy).<\/p>\n NICE & BNF Guidance Context:<\/i> Codeine is classified as a Step 2 weak opioid on the WHO pain ladder. Prescribing guidelines emphasize limiting codeine therapy to the lowest effective dose for short durations ($\\le 3$<\/span> days for acute pain) to avoid tolerance, dependence, and misuse.<\/p>\n Absorption:<\/b> Codeine is rapidly absorbed from the gastrointestinal tract following oral administration, reaching peak plasma concentrations ($T_{max}$<\/span>) in 1 to 2 hours. Oral bioavailability is approximately 40% to 70% due to first-pass metabolism.<\/p>\n<\/li>\n Distribution:<\/b> Codeine distributes widely throughout body tissues with a volume of distribution ($V_d$<\/span>) of $3\\text{ to }6\\text{ L\/kg}$<\/span>. Plasma protein binding is low (10% to 25%). It crosses the placental barrier and is excreted into breast milk.<\/p>\n<\/li>\n Biotransformation:<\/b> Codeine undergoes hepatic Phase I biotransformation via two key enzymatic pathways:<\/p>\n O-demethylation<\/i> (approx. 10%) via CYP2D6 to morfina<\/b> (the active analgesic metabolite).<\/p>\n<\/li>\n N-demethylation<\/i> (approx. 80%) via CYP3A4 to norcodeine.<\/p>\n<\/li>\n Glucuronidation<\/i> (Phase II) via UGT2B7 to codeine-6-glucuronide.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n CYP2D6 Polymorphism Risk:<\/i><\/p>\n Ultra-Rapid Metabolists:<\/b> Accelerated conversion by CYP2D6 can cause rapid accumulation of morphine, leading to severe toxicity and life-threatening respiratory depression even at low doses like 10 mg.<\/p>\n<\/li>\n Poor Metabolists:<\/b> Lack of functional CYP2D6 prevents conversion to morphine, resulting in inadequate pain relief.<\/p>\n<\/li>\n Elimination:<\/b> Excretion occurs primarily via the kidneys, with 86% to 90% of the dose eliminated in urine within 24 hours as free or conjugated metabolites. The elimination half-life ($t_{1\/2}$<\/span>) of codeine ranges between 2.5 and 3.5 hours.<\/p>\n<\/li>\n<\/ul>\n Codeine depresses central nociceptive transmission, suppresses the medullary cough reflex, slows gastrointestinal motility, and reduces central nervous system arousal.<\/p>\n Very Common ($\\ge 1\/10$<\/span>):<\/b> Constipation, somnolence, nausea.<\/p>\n<\/li>\n Common ($\\ge 1\/100$<\/span> to $<1\/10$<\/span>):<\/b> Dizziness, headache, lightheadedness, vomiting, dry mouth, abdominal discomfort, sweating, fatigue.<\/p>\n<\/li>\n Uncommon ($\\ge 1\/1,000$<\/span> to $<1\/100$<\/span>):<\/b> Confusion, dysphoria, euphoria, miosis, palpitations, orthostatic hypotension, pruritus, rash, urinary retention.<\/p>\n<\/li>\n Rare ($\\ge 1\/10,000$<\/span> to $<1\/1,000$<\/span>):<\/b> Severe respiratory depression, bronchospasm, biliary spasm, paralytic ileus, hallucinations.<\/p>\n<\/li>\n Frequency Unknown:<\/b> Drug dependence, tolerance, hyperalgesia, withdrawal syndrome.<\/p>\n<\/li>\n<\/ul>\n Hypersensitivity to codeine, morphine, or formulation excipients.<\/p>\n<\/li>\n Acute severe respiratory depression, severe obstructive airways disease, or acute asthma attacks.<\/p>\n<\/li>\n Known CYP2D6 ultra-rapid metabolists.<\/p>\n<\/li>\n Paediatric patients under 12 years of age.<\/p>\n<\/li>\n Paediatric patients (12\u201318 years) undergoing tonsillectomy or adenoidectomy for obstructive sleep apnoea.<\/p>\n<\/li>\n Breastfeeding mothers (risk of infant morphine toxicity).<\/p>\n<\/li>\n Raised intracranial pressure or severe head injury.<\/p>\n<\/li>\n<\/ul>\n CNS Depressants & Alcohol:<\/b> Concurrent use with alcohol, sedatives, hypnotics, antipsychotics, or other opioids produces additive central nervous system depression, profound hypotension, and respiratory arrest.<\/p>\n<\/li>\n CYP2D6 Inhibitors:<\/b> Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion, quinidine) inhibit the metabolic activation of codeine to morphine, markedly reducing analgesic efficacy.<\/p>\n<\/li>\n CYP3A4 Inhibitors \/ Inducers:<\/b> CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increase codeine shifting through CYP2D6, potentially elevating morphine levels. CYP3A4 inducers (e.g., rifampicin, carbamazepine) decrease codeine efficacy.<\/p>\n<\/li>\n MAOIs:<\/b> Use alongside monoamine oxidase inhibitors or within 14 days of cessation may precipitate serotonin syndrome or acute respiratory depression.<\/p>\n<\/li>\n<\/ul>\n Dependence and Withdrawal:<\/b> Even low-dose codeine (10 mg) can induce physical dependence with continuous use over extended periods. Abrupt discontinuation after chronic intake causes withdrawal symptoms (restlessness, sweating, lacrimation, diarrhoea, anxiety).<\/p>\n<\/li>\n Hepatic & Renal Impairment:<\/b> Clearance is reduced in liver or kidney failure; dose adjustments or longer administration intervals are required.<\/p>\n<\/li>\n Driving and Psychomotor Control:<\/b> Codeine may cause drowsiness or altered reaction times. Patients should not drive or operate machinery if they experience sedation or dizziness<\/p>\n<\/li>\n<\/ul>\n\n 2. Mechanism of Action and Pharmacodynamics<\/h2>\n
3. Approved UK Clinical Indications and Therapeutic Scope<\/h2>\n
\n
4. Pharmacokinetic Profile and Metabolic Fate<\/h2>\n
\n
\n
\n
5. Physiological Effects and Adverse Event Spectrum<\/h2>\n
Adverse Drug Reaction Spectrum<\/h3>\n
\n
6. Contraindications, Drug Interactions, and Clinical Precautions<\/h2>\n
Contraindicaciones<\/h3>\n
\n
Key Drug Interactions<\/h3>\n
\n
Clinical Precautions and Monitoring<\/h3>\n
\n